NCT06023173View on ClinicalTrials.gov

Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

CompletedOBSERVATIONAL
Enrollment

307

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
The Patients With CRLM Who Benefit More From Bevacizumab
Interventions
DIAGNOSTIC_TEST

Deep radiomics-based fusion model

This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.

Trial Locations (1)

Unknown

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06023173 - Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases | Biotech Hunter | Biotech Hunter